Statins Do Not Need to Be Reduced or Discontinued During Oral Terbinafine Therapy
Statins can be safely continued at their current dose while taking oral terbinafine for onychomycosis, as terbinafine has minimal drug-drug interactions and does not significantly interact with statins.
Evidence for Minimal Drug Interactions
The British Association of Dermatologists guidelines explicitly state that "oral terbinafine has minimal drug–drug interactions. The only potentially significant drug interaction with terbinafine is with drugs metabolized by the cytochrome P450 2D6 isoenzyme" 1. Statins are not metabolized by CYP2D6, making this interaction irrelevant.
The FDA drug label for terbinafine lists specific medications that may interact with terbinafine, including medicines for depression, blood pressure, heart problems, desipramine, caffeine, cyclosporine, fluconazole, rifampin, and cimetidine 2. Notably, statins are not mentioned anywhere in the FDA labeling as requiring dose adjustment or discontinuation.
Metabolic Pathways
Terbinafine is primarily cleared by the kidney, with 99% binding to plasma proteins 1. Most statins are metabolized through different cytochrome P450 pathways (primarily CYP3A4 for simvastatin, lovastatin, and atorvastatin; CYP2C9 for fluvastatin) or are not extensively metabolized (pravastatin, rosuvastatin). Since terbinafine's only significant interaction is with CYP2D6 substrates, there is no mechanistic basis for a clinically significant interaction with statins.
Clinical Approach
Continue statin therapy unchanged when initiating terbinafine for onychomycosis. The standard terbinafine regimen is:
- Fingernail onychomycosis: 250 mg daily for 6 weeks
- Toenail onychomycosis: 250 mg daily for 12-16 weeks 1
Important Monitoring Considerations
While statins don't need adjustment, baseline liver function tests (ALT and AST) should be obtained before starting terbinafine 1, 2. This is a standard precaution for terbinafine itself, not due to statin interaction. Baseline monitoring is particularly important in patients with:
- History of heavy alcohol consumption
- Pre-existing hepatitis
- Hematological abnormalities
- Active or chronic liver disease (in which case terbinafine is contraindicated) 1
Common Pitfall to Avoid
Do not confuse terbinafine with itraconazole, which does have significant drug interactions with statins. Itraconazole is a potent CYP3A4 inhibitor and can substantially increase statin levels, particularly with simvastatin and lovastatin, increasing the risk of myopathy and rhabdomyolysis. The American Heart Association guidelines address statin-azole interactions 3, but these concerns do not apply to terbinafine, which is an allylamine antifungal, not an azole.
Interesting Research Note
While not clinically relevant to the question of whether to adjust statins during terbinafine therapy, research has shown that statins themselves possess antifungal properties against dermatophytes, with synergistic effects when combined with terbinafine in vitro 4. However, this does not translate to a clinical recommendation for combination therapy.